Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-11-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Cellid Co., Ltd.' (주식회사 셀리드) covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial information, business operations, management discussions, and corporate governance details, which is characteristic of an interim financial report. It is not a mere announcement or certification, as it provides substantive financial data and business analysis. 9M 2024
2024-11-14 Korean
투자판단관련주요경영사항(임상시험결과) (COVID19 예방 백신 AdCLDCoV191 OMI의 제1/2상 임상시험 결과)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing from the Korean stock exchange (KIND) regarding 'Major Management Matters' (투자판단 관련 주요경영사항). It details the results of a Phase 1/2 clinical trial for a COVID-19 vaccine. Since this is a direct disclosure of clinical trial results to the regulatory body and the public, and it does not fit into specific categories like 'Earnings Release' or 'Annual Report', it falls under the 'Regulatory Filings' (RNS) category as a standard corporate disclosure for material events.
2024-11-06 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Amendment Report) to a previously submitted filing regarding stock option grants. It details changes in the number of recipients and the total number of shares granted due to employee departures. This type of disclosure regarding capital structure and equity-based compensation, filed with the financial regulatory authority, falls under the category of general regulatory filings as it does not fit into specific categories like M&A, dividends, or director dealings.
2024-10-28 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly marked as a '정정신고' (Correction Report). It details changes to previously reported stock option grants, including adjustments to the number of recipients and the total number of shares granted. This type of disclosure regarding capital structure and equity-based compensation, filed with the financial regulatory authority, falls under the category of general regulatory filings as it does not fit into specific categories like M&A, dividends, or director dealings.
2024-10-28 Korean
[기재정정]주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). The document explicitly states it is a '정정신고' (Correction Report) for a previously submitted filing. This type of document falls under the category of Major Shareholding Notification (MRQ) as it details changes in significant share ownership levels.
2024-09-06 Korean
[기재정정]증권발행실적보고서
Share Issue/Capital Change Classification · 100% confidence The document is a '증권발행실적보고서' (Report on the Results of Securities Issuance) filed by Cellid Co., Ltd. It details the final results of a capital increase (rights offering/public offering), including shareholding changes, subscription status, and the use of proceeds. This is a standard regulatory filing in Korea (DART system) that reports the outcome of a previously announced securities issuance. It is not an announcement of a report (RPA) but the report itself, and it fits the 'Share Issue/Capital Change' category.
2024-09-06 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.